<DOC>
	<DOCNO>NCT02661971</DOCNO>
	<brief_summary>Previous study provide strong theoretical rationale conduct randomize study evaluate efficacy safety ramucirumab combination FLOT perioperative treatment resectable adenocarcinoma stomach GEJ .</brief_summary>
	<brief_title>FLOT vs. FLOT/Ramucirumab Perioperative Therapy Gastric GEJ Cancer ( RAMSES )</brief_title>
	<detailed_description>This multicenter , randomize , control , open-label study include patient locally advance adenocarcinoma stomach GEJ schedule receive perioperative chemotherapy . The scope phase II portion trial evaluate pathological response rate either regimen assess centralized pathology evaluate safety tolerability . Patients locally advance esophagogastric adenocarcinoma ( i.e . cT2 N T N-positive ) exclusion distant metastasis include trial . Patients centrally review stratified tumor site ( GEJ vs. gastric ) , histological type ( intestinal vs. diffuse/mixed unknown ) clinical stage ( T1/2 vs. T3/4 and/or N+ ) randomize 1:1 receive either FLOT ( Arm A ) FLOT/ramucirumab ( Arm B ) . Arm A ( FLOT ) Patients randomize Arm A receive 4 pre-operative cycle ( 8 week ) biweekly FLOT ( Docetaxel 50 mg/m² 250 ml NaCl 0.9 % , iv 1 h ; Oxaliplatin 85 mg/m² 500 ml G5 % , iv 2h ; Leucovorin 200 mg/m² 250 ml NaCl 0.9 % , iv 30 min ; 5-FU 2600 mg/m² , iv 24 h , q2wk ) preoperative treatment phase . Surgery Arm A plan occur 4 6 week d1 last FLOT . Patients receive 4 additional post-operative cycle ( 8 week ) FLOT post-operative treatment phase . Post-operative treatment start 6 8 week , maximum 12 week surgery . Arm B ( FLOT/ramucirumab ) Patients randomized Arm B receive ramucirumab 8mg/kg i.v . 60 min combination FLOT regimen , administer identical Arm A described . Surgery Arm B plan occur 4 6 week d1 last FLOT/ramucirumab dose ( never earlier 4 week d1 last FLOT/ramucirumab dose ) . Patients receive 4 additional post-operative cycle ( 8 week ) FLOT/ramucirumab post-operative treatment phase follow total 16 cycle ramucirumab monotherapy ( q2wk ) , start 2 week d1 last cycle FLOT/ramucirumab . In arm , tumor assessment ( CT MRI ) perform randomization prior surgery , every 3 month thereafter progression/relapse , death end follow-up . A change CT MRI follow period possible time . During treatment , clinical visit ( blood cell count , detection toxicity ) occur prior every treatment dose . Safety FLOT/ramucirumab monitor continuously careful monitor adverse event ( AEs ) serious adverse event ( SAEs ) report .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically confirm , resectable adenocarcinoma gastroesophageal junction ( AEG IIII ) stomach ( uT2 , uT3 , uT4 , N category , M0 ) , T N+ M0 patient , follow specification : 1 . Medical technical operability 2 . Participating site PETRARCA study : Negative HER2 detection ( score IHC HER2 0 IHC HER2 1+ ) ; IHC HER2 2+ negative FISH , SISH CISH 2 . No precede cytotoxic target therapy 3 . No prior partial complete tumor resection 4 . Female male patient ≥ 18 ≤ 70 year . Patients reproductive age must willing use adequate contraception study 7 month end ramucirumab treatment ( Appropriate contraception define surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) ) . Female patient childbearing potential need negative pregnancy test within 7 day study start . 5 . ECOG ≤ 1 6 . Exclusion distant metastasis CT MRI abdomen , pelvis , thorax , bone scan MRI ( bone metastases suspect due clinical sign ) . Exclusion infiltration adjacent organ structure CT MRI . 7 . Laparoscopic exclusion peritoneal carcinomatosis , case ascites , peritoneal mass , otherwise suspect clinically 8 . Adequate hematological , hepatic renal function parameter : 1 . Leukocytes ≥ 3000/mm³ , platelet ≥ 100,000/mm³ , neutrophil count ( ANC ) ≥1000/µL , hemoglobin ≥9 g/dL ( 5.58 mmol/L ) , 2 . Adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 , partial thromboplastin time ( PTT ) ≤ 5 second ULN ( unless receive anticoagulation therapy ) . Patients receive warfarin/phenprocoumon must switch low molecular weight heparin achieve stable coagulation profile prior randomization . 3 . Serum creatinine ≤ 1.5 x upper limit normal 4 . Urinary protein ≤1+ dipstick routine urinalysis ( UA ; urine dipstick routine analysis ≥2+ , 24hour urine collection protein must demonstrate &lt; 1000 mg protein 24 hour allow participation protocol ) . 5 . Bilirubin ≤ 1.5 x upper limit normal , AST ALT ≤ 3.0 x upper limit normal , alkaline phosphatase ≤ 6 x upper limit normal 9 . Patient able willing provide write informed consent comply study protocol plan surgical procedure 1 . Known hypersensitivity ramucirumab , 5FU , leucovorin , oxaliplatin , docetaxel 2 . Other known contraindication ramucirumab , 5FU , leucovorin , oxaliplatin , docetaxel 3 . Clinically significant active coronary heart disease , cardiomyopathy congestive heart failure , NYHA IIIIV 4 . Any arterial thromboembolic event , include limited myocardial infarction , transient ischemic attack , cerebrovascular accident , unstable angina , within 6 month prior enrollment . 5 . Uncontrolled poorlycontrolled hypertension ( &gt; 160 mmHg systolic &gt; 100 mmHg diastolic &gt; 4 week ) despite standard medical management . 6 . Clinically significant valvular defect 7 . Past current history malignancy curatively treat without evidence disease 5 year , except curatively treat basal cell carcinoma skin situ carcinoma cervix 8 . Criteria unresectability , e.g . : Radiologically document evidence major blood vessel invasion encasement cancer . Patients involve retroperitoneal ( e.g . paraaortal , paracaval interaortocaval lymph node ) mesenterial lymph node ( distant metastasis ! ) 9 . Known brain metastasis 10 . Other severe internal disease acute infection 11 . Peripheral polyneuropathy ≥ NCI Grade II 12 . Chronic inflammatory bowel disease 13 . Grade 34 GI bleeding within 3 month prior enrollment . 14 . History gastric perforation fistulae past 6 month 15 . Serious nonhealing wound , ulcer , bone fracture within 28 day prior enrollment . 16 . The patient undergone major surgery within 28 day prior enrollment except stag laparoscopy . 17 . Receiving chronic antiplatelet therapy , include aspirin ( Oncedaily aspirin use ( maximum dose 325 mg/day ) permit ) , nonsteroidal antiinflammatory drug ( include ibuprofen , naproxen , others ) , dipyridamole clopidogrel , similar agent . 18 . History deep vein thrombosis , pulmonary embolism , significant thromboembolism ( venous port catheter thrombosis superficial venous thrombosis consider `` significant '' ) 3 month prior randomization . 19 . Cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy ascites . 20 . Ontreatment participation another clinical study period 30 day prior inclusion study 21 . Subject pregnant breast feeding , plan become pregnant within 7 month end treatment . 22 . Patients close institution accord authority court decision ( AMG § 40 , Abs . 1 No . 4 ) 23 . Any concurrent antineoplastic treatment include irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>